INFLARX N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.4 USD | -2.10% |
|
+16.67% | -14.11% |
| 08/05 | InflaRx N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 21/03 | Transcript : InflaRx N.V. - Special Call |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 407K 443K 36.97M | Sales 2025 * | 1.37M 1.49M 125M | Capitalization | 75.85M 82.57M 6.89B |
|---|---|---|---|---|---|
| Net income 2024 * | -46M -50.08M -4.18B | Net income 2025 * | -61M -66.41M -5.54B | EV / Sales 2024 * | 59.7 x |
| Net cash position 2024 * | 51.55M 56.12M 4.68B | Net cash position 2025 * | 7.3M 7.94M 663M | EV / Sales 2025 * | 50 x |
| P/E ratio 2024 * |
-1.74
x | P/E ratio 2025 * |
-1.5
x | Employees | 62 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.66% |
More Fundamentals
* Assessed data
More news
Latest transcript on InflaRx N.V.
More recommendations
More press releases
More news
| 1 day | -2.10% | ||
| 1 week | +16.67% | ||
| Current month | +2.19% | ||
| 1 month | +0.72% | ||
| 3 months | -9.09% | ||
| 6 months | -3.45% | ||
| Current year | -14.11% |
1 week
1.17
1.48
1 month
1.171.48
Current year
1.172.10
1 year
1.144.92
3 years
0.787.25
5 years
0.7842.99
10 years
0.7853.10
| Managers | Title | Age | Since |
|---|---|---|---|
Renfeng Guo
FOU | Founder | 53 | 01/07/01 |
Niels Riedemann
FOU | Founder | 51 | 01/07/01 |
Thomas Taapken
DFI | Director of Finance/CFO | 59 | 01/20/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Nicolas Fulpius
FOU | Founder | 51 | 01/07/01 |
Niels Riedemann
FOU | Founder | 51 | 01/07/01 |
Renfeng Guo
FOU | Founder | 53 | 01/07/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/24/15 | 1.4 | -2.10% | 82,515 |
| 14/24/14 | 1.43 | +14.40% | 300,648 |
| 13/24/13 | 1.25 | +5.93% | 145,253 |
| 10/24/10 | 1.18 | -1.67% | 226,429 |
| 09/24/09 | 1.2 | 0.00% | 306,652 |
Delayed Quote Nasdaq, May 16, 2024 at 01:30 am IST
More quotes
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Calendar
05/06/2024
- R&D Day
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.288
EUR
Average target price
8.375
EUR
Spread / Average Target
+550.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.11% | 84.2M | |
| +7.52% | 111B | |
| +11.38% | 106B | |
| -12.64% | 22.24B | |
| +0.44% | 21.25B | |
| -4.18% | 18.97B | |
| -37.85% | 18.52B | |
| -8.58% | 16.81B | |
| +37.41% | 12.54B | |
| -23.95% | 8.09B |
- Stock Market
- Equities
- IFRX Stock